JP2020529396A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529396A5 JP2020529396A5 JP2019572809A JP2019572809A JP2020529396A5 JP 2020529396 A5 JP2020529396 A5 JP 2020529396A5 JP 2019572809 A JP2019572809 A JP 2019572809A JP 2019572809 A JP2019572809 A JP 2019572809A JP 2020529396 A5 JP2020529396 A5 JP 2020529396A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- solvate
- hydrate
- substituted
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 31
- 150000003839 salts Chemical class 0.000 claims 28
- 239000012453 solvate Substances 0.000 claims 27
- -1 amino-substituted pyridine Chemical class 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 206010016654 Fibrosis Diseases 0.000 claims 7
- 230000004761 fibrosis Effects 0.000 claims 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 102100033145 Cyclin-dependent kinase 19 Human genes 0.000 claims 3
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims 3
- 101000944345 Homo sapiens Cyclin-dependent kinase 19 Proteins 0.000 claims 3
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- 102100032827 Homeodomain-interacting protein kinase 2 Human genes 0.000 claims 2
- 101001066401 Homo sapiens Homeodomain-interacting protein kinase 2 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 230000002414 glycolytic effect Effects 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- MWNFIECEFKUCHS-UHFFFAOYSA-N CC1=C2C=CN=CC2=C2C(=C1)C=C(C=C2)C(=O)O Chemical compound CC1=C2C=CN=CC2=C2C(=C1)C=C(C=C2)C(=O)O MWNFIECEFKUCHS-UHFFFAOYSA-N 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 0 CC***c(cc1)cc2c1c(c(*)ncc1)c1c(C)c2 Chemical compound CC***c(cc1)cc2c1c(c(*)ncc1)c1c(C)c2 0.000 description 7
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539237P | 2017-07-31 | 2017-07-31 | |
| US62/539,237 | 2017-07-31 | ||
| PCT/US2018/044663 WO2019028059A1 (en) | 2017-07-31 | 2018-07-31 | ANTICANCER COMPOUNDS / ANTI-FIBROSIS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529396A JP2020529396A (ja) | 2020-10-08 |
| JP2020529396A5 true JP2020529396A5 (enExample) | 2021-09-09 |
| JP7277390B2 JP7277390B2 (ja) | 2023-05-18 |
Family
ID=65233035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572809A Active JP7277390B2 (ja) | 2017-07-31 | 2018-07-31 | 抗癌／抗線維症化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11932606B2 (enExample) |
| EP (1) | EP3661512A4 (enExample) |
| JP (1) | JP7277390B2 (enExample) |
| CN (1) | CN111447931B (enExample) |
| CA (1) | CA3067871A1 (enExample) |
| WO (1) | WO2019028059A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7277390B2 (ja) * | 2017-07-31 | 2023-05-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗癌／抗線維症化合物 |
| WO2021021953A2 (en) | 2019-07-30 | 2021-02-04 | Sanford Burnham Prebys Medical Discovery Institute | Dopamine receptor d1 agonists and methods of use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648021A (en) * | 1994-01-17 | 1997-07-15 | Hoechst Aktiengesellschaft | Phenanthrene derivatives and their use in liquid-crystalline mixtures |
| DE19524230A1 (de) * | 1995-07-04 | 1997-01-09 | Hoechst Ag | Fluorierte Phenanthren-Derivate und ihre Verwendung in flüssigkristallinen Mischungen |
| CN1214073A (zh) * | 1995-07-17 | 1999-04-14 | 德国赫彻斯特研究技术两合公司 | 铁电性液晶混合物 |
| AU2006269504A1 (en) * | 2005-07-08 | 2007-01-18 | Merck Sharp & Dohme Corp. | Inhibitors of checkpoint kinases |
| BRPI0719123A2 (pt) * | 2006-09-01 | 2013-12-17 | Cylene Pharmaceuticals Inc | Moduladores de serina-treonina proteína cinase e parp |
| WO2009097014A2 (en) * | 2007-08-31 | 2009-08-06 | Cylene Pharmaceuticals, Inc. | Therapeutic kinase modulators |
| US20100267753A1 (en) * | 2009-04-17 | 2010-10-21 | Mustapha Haddach | Methods of treating disorders associated with protein kinase ck2 activity |
| BR112012005970A2 (pt) | 2009-09-16 | 2015-09-08 | Cylene Pharmaceuticals Inc | moduladores tricíclicos de proteína quinase |
| US10432142B2 (en) * | 2017-07-21 | 2019-10-01 | Oracle International Corporation | Voltage controlled oscillator with tunable inductor and capacitor |
| JP7277390B2 (ja) * | 2017-07-31 | 2023-05-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗癌／抗線維症化合物 |
-
2018
- 2018-07-31 JP JP2019572809A patent/JP7277390B2/ja active Active
- 2018-07-31 WO PCT/US2018/044663 patent/WO2019028059A1/en not_active Ceased
- 2018-07-31 CN CN201880049675.1A patent/CN111447931B/zh active Active
- 2018-07-31 EP EP18840434.7A patent/EP3661512A4/en not_active Withdrawn
- 2018-07-31 US US16/634,063 patent/US11932606B2/en active Active
- 2018-07-31 CA CA3067871A patent/CA3067871A1/en active Pending